Hepatitis C Therapy
Phase III trial of Albuferon/ribavirin combo underway in treatment-naive HCV patients
Published in Health Business Week, January 19th, 2007
Albuferon is being developed by HGS and Novartis under an exclusive worldwide development and commercialization agreement entered into in June 2006.
"We are pleased to advance Albuferon to phase III clinical trials," said H. Thomas Watkins, president and CEO, HGS. "Hepatitis C is the most common chronic blood-borne infection in the developed world. We believe that Albuferon could...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2007-01-19)
More Articles from Health Business Week
- Adverse Drug Reaction
Bayer informs healthcare professionals of safety revisions to the Trasylol label - Alzheimer Disease
Dosing commenced in Phase IIa trial of PBT2 in early Alzheimer patients - Anemia
Roche submits added data to U.S. FDA to support license application for anti-anemia agent - Anthrax Vaccine
U.S. Health & Human Services cancels VaxGen's anthrax vaccine contract - Antibacterial Agents
New Drug Application submitted for investigational antibiotic Doripenem - Asthma
Half of newly diagnosed asthmatics do not fill prescriptions within a year of diagnosis - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
